Autres langues Fusen Pharmaceutical Company Limited

Actions

1652

KYG370981030

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:09:00 03/05/2024			Varia. 5j.	Varia. 1 janv.
0,88 ^HKD	-1,12%		-2,22%	-35,77%

04/04	L'organisme de réglementation chinois accepte la demande de Fusen Pharmaceutical pour un médicament contre le diabète de type 2	MT
03/04	Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited annonce que l'Administration nationale des produits médicaux de la République populaire de Chine a accepté la demande de lancement de Metformin Empagliflozin Tablets (I)	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Fusen Pharmaceutical's Type 2 Diabetes Drug Application Accepted by Chinese Regulator	04/04
Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Announces National Medical Products Administration of the People's Republic of China Accepts the Application for Launching Metformin Empagliflozin Tablets (I)	03/04
Fusen Pharmaceutical Posts Higher Loss in 2023	01/04
Fusen Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Year Ended 31 December 2023	15/03
Fusen Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2023	29/08/23
Fusen Pharmaceutical Forecasts Return to Profitability in H1	11/08/23
Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2023	10/08/23
Fusen Pharmaceutical Company Limited commences an Equity Buyback Plan for 75,843,900 shares, representing 10% of its issued share capital, under the authorization approved on May 30, 2023.	31/05/23
Fusen Pharmaceutical Company Limited's Equity Buyback announced on June 2, 2022, has expired.	30/05/23
Tranche Update on Fusen Pharmaceutical Company Limited's Equity Buyback Plan announced on June 2, 2022.	28/03/23
Fusen Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2022	28/03/23
Fusen Pharmaceutical Company Limited Does Not Recommend Dividend for the Year Ended 31 December 2022	28/03/23
Fusen Pharmaceutical to Swing to Loss in 2022	14/03/23
Fusen Pharmaceutical Company Limited Provides Earnings Guidance for the Year Ended 31 December 2022	13/03/23
Fusen Pharmaceutical, Directors Hit with Disciplinary Action for Disclosure Breaches	04/01/23
Fusen Pharmaceutical Company Limited Announces Change of Principal Place of Business in Hong Kong	15/12/22
Tranche Update on Fusen Pharmaceutical Company Limited's Equity Buyback Plan announced on June 2, 2022.	29/08/22
Fusen Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2022	29/08/22
Fusen Pharmaceutical Company Limited Does Not Recommend Dividend for the Six Months Ended June 30, 2022	29/08/22

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Fusen Pharmaceutical Company Limited

Actions

1652

KYG370981030

Autres langues

Filtres